11 - 13 September 2012, Jumeirah Carlton Tower, London, UK
Get competitive insight into global regulatory strategies, and find out how to successfully bring biosimilars to-market in developed and developing regions. With leading companies from India, Israel, Switzerland, UK, USA, Germany and more speaking at the World Biosimilars Congress, this is a great opportunity to get a complete overview of the development pathway for biosimilars in your region of interest, and find out which other lucrative markets you should be targeting.
- Compare regulatory pathways for biosimilars in developed and developing markets
- Get critical insight on to-market models from Teva and Sandoz in the EU and US, and beyond
- Debate the minimum level of clinical testing required for a safe and approvable product
- Consider the best options for product selection based on market analysis and competitive landscape
- Find out how to design a patent-dispute pathway to avoid IP infringement
- Understand how to demonstrate biosimilarity with comparability to the reference product
- Ensure that immunogenicity standards are kept seamless from development to in-clinic
- Learn about new frontiers in cell line development and the opportunities for biosimilar manufacture
- Find out how to improve bioprocessing and production of biosimilars
- Network with regulators, drug manufacturers and service providers to assess and secure new partners
Download the brochure for more information.
To book your place contact: Marcia Ardila on email: marcia.ardila@terrapinn.com or register your place online at http://www.terrapinn.com/2012/biosimilars-congress